Dissolution Technologies is a premier journal dedicated to advancing the field of pharmaceutical science, particularly in the critical area of dissolution testing and its broader implications in drug development and delivery systems. Published by Dissolution Technologies, Inc. in the United States, this journal has been a vital resource for researchers, professionals, and students since its inception in 1996, with its coverage extending to 2024. While it currently holds a respectable Q3 quartile ranking in the Pharmaceutical Science category, the journal continues to strive towards increasing its visibility and impact, evidenced by its Scopus rank of #117 out of 183 in the domain of Pharmacology, Toxicology, and Pharmaceutics. Although it operates under a non-open access model, the journal offers invaluable insights and cutting-edge research articles that support the academic and practical needs of the pharmacological community, addressing essential topics in drug solubility and formulation. Whether you are an established researcher or a new student in the field, Dissolution Technologies remains an essential source for current knowledge and emerging trends within this critical aspect of pharmaceutical sciences.

Pharmaceutical Medicine is a leading journal published by SPRINGER INT PUBL AG, dedicated to the field of pharmacology and pharmaceutical sciences. With ISSN 1178-2595 and E-ISSN 1179-1993, this journal serves as an essential platform for researchers and professionals to share groundbreaking findings and advancements in medication efficacy, safety, and innovative therapeutic strategies. Recognized for its contribution to the field, Pharmaceutical Medicine holds an impressive Q2 ranking in both Pharmacology and Medical Pharmacology categories, further underscored by its competitive Scopus rankings—positioned at 100/272 (63rd percentile) in Medical Pharmacology and 156/313 (50th percentile) in Pharmacology, Toxicology, and Pharmaceutics. Although it primarily operates on a traditional subscription basis, its robust academic reputation continues to attract a diverse readership worldwide. Addressed in the United Kingdom with facilities in Switzerland, the journal publishes authoritative articles from its inception in 2000 through to 2024, making it a pivotal resource for those seeking to enhance their understanding and application of pharmacological principles in clinical practice and research.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY is a premier journal published by Taylor & Francis Ltd that focuses on the latest advancements and innovations in the field of pharmaceutical science. Established in 1996, this journal has evolved to encompass a wide array of interdisciplinary studies relevant to drug development, formulation technology, and delivery systems, serving as a platform for researchers and professionals to share groundbreaking findings. With an impressive impact factor and ranked in both Q2 in Pharmaceutical Science and Q3 in Medicine (miscellaneous), it positions itself among the top-tier journals in pharmacology and toxicology. The journal's insights are critical for scholars and practitioners aiming to enhance therapeutic efficacy and safety. Access options for the content remain traditional, thus supporting a comprehensive approach to scientific literature. Throughout its converged years up to 2024, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY continues to play a vital role in shaping pharmaceutical education and practice.

Tropical Journal of Pharmaceutical Research is an esteemed open-access platform dedicated to advancing the field of pharmaceutical sciences, published by the Pharmacotherapy Group in Nigeria. With an ISSN of 1596-5996 and open access established since 2002, this journal serves as a critical resource for researchers, professionals, and students seeking to disseminate and access high-quality research in both pharmaceutical science and pharmacology. Despite its ranking in the third quartile (Q3) for Pharmaceutical Science and the fourth quartile (Q4) in Pharmacology as of 2023, the journal continues to stand out with its commitment to fostering significant dialogue and innovation in the scientific community. Anchored at the University of Benin, Faculty of Pharmacy, the journal invites contributions that explore novel pharmaceutical research, clinical applications, and drug development, playing a vital role in addressing health challenges that are particularly relevant to tropical regions. Researchers can look forward to publishing their findings in a journal that not only promotes the sharing of knowledge but also enhances the scientific discourse within a rapidly evolving field.

The Journal of Pharmaceutical and Biomedical Analysis, published by ELSEVIER and available in print and online formats, stands as a pivotal source of knowledge in the realms of Analytical Chemistry, Clinical Biochemistry, Drug Discovery, and Pharmaceutical Science. With an ISSN of 0731-7085 and an e-ISSN of 1873-264X, this journal is dedicated to publishing high-quality research that advances the understanding and development of analytical techniques in pharmaceuticals and biomedicine. The journal has earned a solid reputation, reflected in its Q2 category rankings across five distinct fields for 2023, and boasts impressive Scopus rankings, signaling its robust impact within the academic community. The Journal of Pharmaceutical and Biomedical Analysis serves as an essential resource for researchers, professionals, and students alike, providing actionable insights and fostering innovation that can directly influence future advancements in drug development and biomedical applications.

MOLECULAR PHARMACEUTICS, published by the American Chemical Society, stands as a pivotal journal within the fields of Drug Discovery, Molecular Medicine, and Pharmaceutical Science, as evidenced by its impressive rankings in various categories, including Q1 in Drug Discovery and Pharmaceutical Science. With an ISSN of 1543-8384 and an E-ISSN of 1543-8392, this journal has been at the forefront of research since its inception in 2004 and continues to foster innovation and collaboration among researchers, professionals, and students well into 2024. The journal is noted for its significant impact, having achieved a Scopus ranking of #31 in Pharmaceutical Science and #36 in Drug Discovery, placing it in the top percentiles of the respective fields. While it currently does not offer Open Access, MOLECULAR PHARMACEUTICS remains an essential resource for advancing the understanding of molecular mechanisms in drug development and therapeutic strategies, ensuring that cutting-edge findings reach a wide audience and contribute to the progression of pharmaceutical sciences.

The Journal of Intellectual Property Law & Practice, published by Oxford University Press, is a premier academic journal dedicated to the exploration and discussion of issues surrounding intellectual property law. With an ISSN of 1747-1532 and an E-ISSN of 1747-1540, this journal has established itself as an essential resource in the field, featuring high-quality articles that contribute to the advancement of legal scholarship and practice. Recognized in the 2023 Category Quartiles as Q2 in Law, the journal ranks within the top half of its field and provides a global platform for researchers, practitioners, and policymakers. Covering a comprehensive range of topics from copyright to patent law, the journal encourages interdisciplinary dialogue and aims to bridge academic and professional practice. Although it operates under subscription models, it ensures wide accessibility of its rigorous content and analysis, maintaining its significance in shaping the discourse on intellectual property law from its inception in 2005 to the anticipated 2024. This journal not only supports scholarly communication but also fosters a community committed to the dynamic challenges of intellectual property in today’s innovative landscape.

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

CARDIOLOGY CLINICS is a prestigious journal published by W B SAUNDERS CO-ELSEVIER INC, offering insightful and comprehensive reviews in the field of cardiology and cardiovascular medicine since its inception in 1983. With its ISSN 0733-8651 and E-ISSN 1558-2264, the journal has established a significant impact factor within the academic community, holding a Q2 ranking in both Cardiology and Cardiovascular Medicine as well as in Medicine (miscellaneous) for 2023. Located in the heart of Philadelphia, USA, it serves as a vital resource for researchers, clinicians, and students seeking to deepen their understanding of cardiovascular diseases and advancements in treatment. Although it operates under a traditional subscription model, the journal remains committed to disseminating valuable knowledge that shapes current practices and informs future research directions. As it converges towards its 2024 issues, CARDIOLOGY CLINICS continues to play an influential role in enhancing the discourse on cardiovascular health worldwide, ensuring that its audience stays at the forefront of clinical and scientific developments.

The Journal of Pharmaceutical Innovation, published by SPRINGER, serves as a vital resource in the fields of Pharmaceutical Science and Drug Discovery. With an ISSN of 1872-5120 and an E-ISSN of 1939-8042, this journal has been disseminating significant research findings since its inception in 2006. It is recognized for its rigorous peer-review process, maintaining a respectable ranking of Q2 in Pharmaceutical Science and Q3 in Drug Discovery as of 2023. Researchers and practitioners benefit from the journal's diverse scope, which encompasses innovative methodologies and advancements in pharmaceuticals, thereby fostering knowledge and collaboration within the scientific community. Although it does not offer Open Access options, the journal is accessible through institutional subscriptions and libraries, ensuring that critical insights in drug development and pharmacology reach a broad audience. The geographical presence of the journal in the United States underscores its influence in shaping the pharmaceutical landscape on a global scale.